1 / 12

The Patient Perspective Ms Ginette Camps-Walsh

The Patient Perspective Ms Ginette Camps-Walsh. Working in partnership with. Improving Interventional Radiology: The need for action. www.femisa.org.uk. UFE- MY FIBROIDS!. AFTER UFE Uterus normal size - much slimmer Kidney normal size Bulk symptoms gone Overall improvement in health

Télécharger la présentation

The Patient Perspective Ms Ginette Camps-Walsh

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Patient PerspectiveMs Ginette Camps-Walsh Working in partnership with

  2. Improving Interventional Radiology: The need for action www.femisa.org.uk Ginette Camps-Walsh FEmISA

  3. UFE- MY FIBROIDS! • AFTER UFE • Uterus normal size - much slimmer • Kidney normal size • Bulk symptoms gone • Overall improvement in health • Feel younger! – playing squash • Would have UFE again • Recommended to many • No early menopause • BEFORE • Uterus 34 weeks - looked pregnant • 4 large fibroids • Enlarged kidney • Heavy & prolonged menstrual bleeding

  4. BENEFITS OF EMBOLISATION Clinical Benefits • Lower mortality than hysterectomy • No surgery, no general anaesthetic, quicker recovery • No possibility of surgical trauma • No haemorrhage, no scars, small incision site • Fewer long-term side effects c.f. hysterectomy - early menopause, prolonged early HRT use, sexual dysfunction, clinical depression, urinary incontinence, vaginal or posterior prolapse, later adhesions • Uterus still intact, maintain fertility & sexual function • Possible to have successful pregnancy Ginette Camps-Walsh FEmISA

  5. BENEFITS OF EMBOLISATION Social Benefits • Overnight hospital stay versus 5-10 days for hysterectomy • Little at home nursing care required • Return to work in 1-2 weeks versus 3 months for surgery • No restriction to lifting or driving • Reduced likelihood of early menopause • Less likelihood of corrective surgery • Maintain fertility & femininity – important to women • Sexual function normally unaffected • Possible to have successful pregnancy Ginette Camps-Walsh FEmISA

  6. BENEFITS OF EMBOLISATION Cost to Patients, their families • 1 night hospital stay vs. 5-10 days hysterectomy • Return to work 1-2 weeks vs. 3 months • Little if any need for care from family • No restriction on driving and lifting • Less need for early HRT Cost to NHS • 1 night stay vs. 5-10 days – freeing resources • UFE less expensive than surgery • Less early HRT etc Ginette Camps-Walsh FEmISA

  7. ECONOMIC BENEFITS Potential Theoretical Savings if all Hysterectomies for Fibroids were replaced by UFE • NHS Savings PbR Tariff £19,367,441 • Saving Hospital Bed Days 77,355 • Savings on working days * 1,137,570 • Economic savings * £100,788,702.00 *Return to work 2 weeks UFE vs. 3 months hysterectomy Ginette Camps-Walsh FEmISA

  8. SERIOUS EQUITY ISSUES WITH UFE Access to UFE – • Confined in the main to assertive, educated women from higher socioeconomic groups • Women from lower socioeconomic groups could arguably benefit more from UFE Clinical Equity for women and men – • Prostatectomy normally confined to cancer treatment • Hysterectomy used inappropriately for many minor gynae problems Shouldn’t such invasive surgery should be confined to cancer treatment? Ginette Camps-Walsh FEmISA

  9. BARRIERS TO ACCESS FOR UFE The NHS Referral System! • Many women are not informed of alternatives to hysterectomy [contrary to NICE & GMC guidelines & NHS white paper] • There is a lack knowledge about UFE & centres offering it • Comparative information on hysterectomy vs. UFE often inaccurate and biased Women are often not given a choice • IRs and gynaecologists should be working together as a team – this is happening • Hysterectomy is second commonest operation in the private sector Ginette Camps-Walsh FEmISA

  10. BARRIERS TO ACCESS FOR UFE Knowledge and Education • NICE guidelines on Heavy Menstrual Bleeding state - women must be offered UFE, hysterectomy and myomectomy – but many are not • Most GPs are unaware of UFE - unable to advise women • Women are not being informed about comparative morbidity & mortality of fibroid treatment objectively, if at all – uninformed patients do not have a choice • Commissioners are unaware of UFE and do not commission it • Commissioners may feel NICE clinical guidelines are expensive • Some PCTs refuse to fund local UFE, although it is cheaper Huge health inequalities – the educated find out for themselves Ginette Camps-Walsh FEmISA

  11. BARRIERS TO ACCESS FOR UFE NHS Procedural Issues • Patients cannot be referred directly to interventional radiologists or use Choose and Book • No proper OPCS codes for UFE so – • No proper PbR tariff • PbR tariffs encourage old invasive treatments e.g. hysterectomy because they pay more • NICE Technology Appraisals commissioning is mandatory, but clinical guidelines and interventional procedures reviews are not • NICE does not consider costs to patients, their families, employers and society – Freddie Earl Howe would like this to change Ginette Camps-Walsh FEmISA

  12. HOW TO IMPROVE ACCESS TO UFE Impetus from on High (DH/Ministers) to – • Ensure every Trust fully informs all patients objectively of all treatment options - audited through PROMS • Sort out proper OPCS codes for UFE and all IR procedures • Change PbR tariffs so less invasive new medical technologies are more profitablefor Trusts • Allow direct access to IRs & through Choose & Book • Set up an education system for GPs and commissioners to ensure they are informed & aware of new medical technologies and IR procedures and commission them 6. Change NICE’s remit to include patient & societal costs and reform medical technology reviews 7. Ensure sufficient NHS resources to meet patient demand. Ginette Camps-Walsh FEmISA

More Related